Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acorda Therapeutics, Inc.
Acorda Therapeutics Reports Third Quarter 2008 Financial Results
November 21st, 2008
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced its financial results for the third quarter of 2008. "We made significant progress this quarter in preparing a New Drug Application for Fampridine-SR, which we expect to submit electronically to the U.S. Food and Drug Administration in the first quarter of 2009. We also concluded a series of meetings with four European regulatory agencies, and as a result are planning to file a Marketing Authorization Application for Fampridine-SR in Europe in 2009," said Ron Cohen, M.D., Acorda Therapeutics' President and CEO. "In addition, we completed a $127 million net equity financing in August, finishing the third quarter in a...
Source: Health Business Week (2008-11-21)
|
